Related Experiment Video
Updated: Aug 15, 2026
Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
Lost in translation: why pharmacological trials keep failing in acute spinal cord injury
Abelardo Q C Araujo1,2,3
1Universidade Federal do Rio de Janeiro, Instituto de Neurologia Deolindo Couto, Rio de Janeiro RJ, Brazil.
Abstract:
Despite four decades of translational research, no pharmacological agent has been approved for acute traumatic spinal cord injury (SCI) based on class-I evidence. The current narrative review critically examines the seven agents evaluated in phase-II to -III clinical trials-methylprednisolone (MPSS), GM-1 monosialotetrahexosylganglioside, minocycline, riluzole, anti-Nogo-A antibody NG101, VX-210, and granulocyte colony-stimulating factor (G-CSF)-with emphasis on quantitative effect estimates, confidence intervals, and mechanisms of translational failure. Polylaminin, under phase-I evaluation approved by the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, ANVISA, in Portuguese), is discussed in the context of disproportionate public communication relative to the stage of evidence; available human data are limited to a small, uncontrolled, unreviewed pilot study insufficient for efficacy inferences. High-dose MPSS conferred no motor recovery benefit in a meta-analysis of 1,863 participants and was significantly associated with gastrointestinal hemorrhage (odds ratio [OR] = 2.07; 95%CI: 1.02-4.20) and respiratory infections (OR = 1.73; 95%CI: 1.12-2.68). Furthermore, GM-1 ganglioside, G-CSF, and VX-210 failed to meet the prespecified primary endpoints. Minocycline produced inconclusive results in an underpowered phase-II study. Riluzole (Riluzole in Spinal Cord Injury Study [RISCIS]), which was prematurely terminated at 55% of enrollment due to the coronavirus disease 2019 (COVID-19) pandemic, showed a significant motor benefit in patients classified as grade C according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) (+8.0 points; 95%CI: 1.5-14.4; 2-tailed p = 0.034). The Nogo Inhibition in Spinal Cord Injury (NISCI) trial (2025), the most methodologically rigorous SCI trial to date, demonstrated no primary endpoint benefit but identified functional signals in motor-incomplete injuries. In total, six structural domains of translational failure are identified and methodological solutions proposed.
Insights
Despite decades of research, no drug has proven effective for acute traumatic spinal cord injury (SCI). This review analyzes seven agents, finding most failed due to translational issues, though riluzole showed promise in specific SCI cases.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- No pharmacological agent has achieved approval for acute traumatic spinal cord injury (SCI) based on class-I evidence despite extensive research.
- Translational research in SCI has faced significant challenges over the past four decades.
Purpose of the Study:
- To critically review seven agents (MPSS, GM-1, minocycline, riluzole, NG101, VX-210, G-CSF) evaluated in phase II-III SCI clinical trials.
- To analyze quantitative effect estimates, confidence intervals, and identify mechanisms of translational failure for these agents.
- To discuss Polylaminin's early-stage evaluation and public communication relative to its evidence level.
Main Methods:
- Narrative review of clinical trial data for seven pharmacological agents in SCI.
- Emphasis on quantitative effect estimates, confidence intervals, and meta-analysis where applicable.
- Examination of mechanisms contributing to translational failure in drug development for SCI.
Main Results:
- High-dose methylprednisolone (MPSS) showed no motor benefit and increased risks of gastrointestinal hemorrhage and respiratory infections.
- GM-1 ganglioside, G-CSF, and VX-210 failed to meet primary endpoints.
- Riluzole demonstrated a significant motor benefit in ASIA Impairment Scale grade C patients, though its trial was terminated early.
- The NISCI trial found no primary benefit for anti-Nogo-A antibody NG101 but suggested functional signals in motor-incomplete injuries.
Conclusions:
- Multiple pharmacological agents have failed to translate into effective treatments for acute traumatic SCI.
- Identified six key domains of translational failure, proposing methodological solutions for future drug development.
- Riluzole and NG101 show potential in specific SCI subgroups, warranting further investigation with improved methodologies.
